British National Formulary for

The exception to this is the case of some sustained-release preparations where the release properties of different brands may vary (for example modified-release diltiazem or theophylline preparations). In these cases, it is usual for patients to be maintained on one particular brand to prevent fluctuations in plasma concentration. See the British National Formulary for further details. 

If you are unfamiliar with the dose of the medication, this will need to be checked. The best reference source for this is the British National Formulary or the British National Formulary for Children, or the Summary of Product Characteristics (SPC), which each pharmaceutical company is obliged to produce for each individual medicinal product. 

Further to general considerations, some drugs may not be used in specific patient groups. These restrictions (termed contraindications) are detailed in the individual drug entry within the British National Formulary or British National Formulary for Children, or the manufacturer s SPC. 

Check Appendix 9 of the British National Formulary for supplementary labelling requirements. Fenbufen British National Formulary label number 21. 

Check Appendix 9 of the British National Formulary for supplementary labelling requirements. Co-magaldrox no additional British National Formulary labels but the pharmaceutical caution to Shake the bottle should be added for the suspension. Oxytetracycline British National Formulary labels number 7, 9 and 23. 

British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child ffealth and the Neonatal and Paediatric Pharmacists Group (current edition). British National Formulary for Children. London The Pharmaceutical Press (updated every year). 

Drugs in current use are not all covered in this text neither is this work intended as a recommendation for any drug use. Professionals should always consult the latest edition of the British National Formulary for definitive information about medicines. 

National Formulary for Children, 2005). Povidone-iodine should be avoided in pregnancy for skin and vaginal disinfection, and also during breast-feeding. It is contraindicated for preterm infants under 32 weeks gestation for infants whose body weight is under 1.5 kg or for regular use in neonates (Weber et al., 1998 Linder et ai, 1997 British National Formulary for Children, 2005). 

Gastello, British National Formulary for Children, (2005). BMJ Publishing Group, London, UK. 

The aim of this chapter is to describe iodine intakes based on the calculated amounts for standard infant formulas available in the UK, and for all proprietary enteral preparations that can be used as standalone feeds for complete nutrition. The proprietary preparations highlighted in this review are those that are fisted in the British National Formulary, and the corresponding version for Children 2006 (British National Formulary for Children, 2006) mostly in the section Appendix A2 Borderline Substances excluding those which we know have been discontinued (from 2007). Enteral supplements which are not the sole source of nutrition have not been included, as potential iodine intake will be variable and dependent on the proportion of enteral supplement consumed, as well as the amount and iodine content of nonsupplemented food. 

---